Janssen received FDA approval to use Risperdal Consta, a long-acting version of bipolar disorder drug Risperdal, in people with bipolar I disorder. The clearance allows the unit of Ortho-McNeil-Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to market the product as either a standalone treatment or a combination therapy with lithium or valproate.

Full Story:
Forbes, Reuters

Related Summaries